Document is current
Any future updates will be listed below
-
Authors
Zhang, Jia
Wang, Tao
Bi, Jianbin
Ke, Mengyun
Ren, Yifan
Wang, Mengzhou
Du, Zhaoqing
Liu, Wuming
Hu, Liangshuo
Zhang, Xiaogang
Liu, Xuemin
Wang, Bo
Wu, Zheng
Lv, Yi
Meng, Lingzhong
Wu, Rongqian
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 81770491, No. 82172167)
Innovation Capacity Support Plan of Shaanxi Province (No. 2020TD-040)
Natural Science Basic Research Program of Shaanxi (No. 2022JQ-899)
- License Information
-
More Information
Article History
Received: 27 November 2022
Accepted: 7 March 2023
First Online: 24 March 2023
Declarations
:
: All subjects signed the informed consent forms and were approved by Internal Review Board of the First Affiliated Hospital of Xi’an Jiaotong University.
: Not applicable.
: Wu R, Zhang J and Bi J are the inventor of a patent (ZL 202010490337.0, China) entitled “The application of HSF2BP in ischemia-reperfusion- or drug-induced liver injury”. This patent covers the fundamental concept of using HSF2BP as a therapeutic target for ischemia-reperfusion- or drug-induced liver injury.
